Page last updated: 2024-08-26

sr141716 and sk&f 82958

sr141716 has been researched along with sk&f 82958 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheng, J; McCorvy, JD; Tan, L; Yan, W	1
Brotchie, JM; Crossman, AR; Maneuf, YP	1
Bisogno, T; Brotchie, JM; Crossman, AR; Di Marzo, V; Hill, MP	1

Reviews

1 review(s) available for sr141716 and sk&f 82958

Article	Year
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22 Topics: Animals; Drug Discovery; Humans; Ligands; Receptors, G-Protein-Coupled; Signal Transduction; Structure-Activity Relationship	2018

Other Studies

2 other study(ies) available for sr141716 and sk&f 82958

Article	Year
The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Experimental neurology, 1997, Volume: 148, Issue:1 Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Locomotion; Male; Morpholines; Naphthalenes; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperidines; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Drug; Reserpine; Rimonabant	1997
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2000, Volume: 14, Issue:10 Topics: Animals; Arachidonic Acids; Benzazepines; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine Agonists; Endocannabinoids; Globus Pallidus; Glycerides; Humans; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Reserpine; Rimonabant; Substantia Nigra; Tissue Distribution	2000

Article

Year

The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.

Experimental neurology, 1997, Volume: 148, Issue:1

Topics: Animals; Basal Ganglia; Benzazepines; Benzoxazines; Dopamine Agonists; gamma-Aminobutyric Acid; Locomotion; Male; Morpholines; Naphthalenes; Nerve Tissue Proteins; Parkinson Disease, Secondary; Piperidines; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Drug; Reserpine; Rimonabant

1997

Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2000, Volume: 14, Issue:10

Topics: Animals; Arachidonic Acids; Benzazepines; Cannabinoid Receptor Modulators; Cannabinoids; Dopamine Agonists; Endocannabinoids; Globus Pallidus; Glycerides; Humans; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Reserpine; Rimonabant; Substantia Nigra; Tissue Distribution

2000